That’s why I Feel Comfortable With Amedisys Inc.’s (AMED) Future

Amedisys Inc. [AMED] stock prices are up 4.32% to $91.25 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AMED shares have gain 4.23% over the last week, with a monthly amount drifted -10.46%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


On 22, November 2022, Amedisys Names Scott Ginn Acting Chief Operating Officer. In a post published today on Yahoo Finance, Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, names Scott Ginn, Executive Vice President and Chief Financial Officer, its Acting Chief Operating Officer, effective immediately.

From an analyst’s perspective:

Amedisys Inc. [NASDAQ: AMED] stock has seen the most recent analyst activity on October 27, 2022, when Raymond James downgraded its rating to a Mkt Perform. Previously, UBS downgraded its rating to Sell on August 02, 2022, and dropped its price target to $95. On June 29, 2022, Stifel initiated with a Hold rating and assigned a price target of $128 on the stock. BofA Securities downgraded its rating to a Underperform and decreased its price target to $102 on June 21, 2022. UBS upgraded its rating to a Neutral but $168 remained the price target by the analyst firm on March 01, 2022. BMO Capital Markets upgraded its rating to Outperform for this stock on February 25, 2022, and downed its price target to $190. In a note dated February 25, 2022, Truist reiterated an Buy rating on this stock and revised its target price from $210 to $200.

The stock price of Amedisys Inc. [AMED] has been fluctuating between $83.00 and $179.91 over the past year. Currently, Wall Street analysts expect the stock to reach $118.00 within the next 12 months. Amedisys Inc. [NASDAQ: AMED] shares were valued at $91.25 at the most recent close of the market. An investor can expect a potential return of 29.32% based on the average AMED price forecast.

Analyzing the AMED fundamentals

The most recent quarter, Amedisys Inc. [NASDAQ:AMED] reported sales of 557.99 billion, representing a surge of 0.80%. Gross Margin for this corporation currently stands at +42.90% with Operating Margin at +11.12%, Pretax Margin comes in at +12.66%, and Net Margin reading is +9.44%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 88.69 points at the first support level, and at 86.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 92.72, and for the 2nd resistance point, it is at 94.20.

Amedisys Inc. [AMED] reported earnings per share of $1.15 for its fiscal quarter that ended on 9/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $1.22/share, meaning a difference of -$0.07 and a surprise factor of -5.70%. By comparison, the stated earnings for the previous quarter ended on 6/29/2022 were $1.47 per share as compared to estimates of $1.23 per share, a difference of $0.24 representing a surprise of 19.50%.

Ratios To Look Out For

It’s worth pointing out that Amedisys Inc. [NASDAQ:AMED]’s Current Ratio is 1.10. Further, the Quick Ratio stands at 0.95, while the Cash Ratio is 0.14. Considering the valuation of this stock, the price to sales ratio is 2.41, the price to book ratio is 5.65 and the P/E (TTM) ratio is 24.70.

Transactions by insiders

Recent insider trading involved Bohnert Denise M., Chief Compliance Officer, that happened on Jun 23 when 557.0 shares were sold. Kemmerly David L completed a deal on Mar 29 to sell 2500.0 shares. Meanwhile, Director LECHLEITER RICHARD A bought 1000.0 shares on Nov 30.